Baxter International, a global leader in biologic medical therapies, announced this week that it will build a $1 billion manufacturing facility in Covington, Georgia to support growth of its plasma-based treatments. The new facility is expected to create more than 1,500 full-time employment positions in Georgia, and over 500 more across multiple U.S. locations. The new facility will support plasma fractionation, purification, fill-finish and include a testing lab.
"This investment demonstrates our long-term commitment to patients around the world who rely on our plasma-based therapies," said Robert L. Parkinson, Jr., Baxter's chairman and chief executive officer.
According to a report in the Atlanta Journal-Constitution state incentives totaling $78 million helped with the decision to locate in Georgia. Furthermore the company could qualify for an estimated $32 million in savings from a sales tax exemption on machinery and equipment plus construction materials included in a new tax law, according to the paper. Another $13.75 million grant comes from the OneGeorgia discretionary fund, as reported by IndustryWeek.
"Baxter's decision to come to Georgia marks a new era in the growth of our biosciences industry and will have far-reaching impact on our economy," said Georgia Governor Nathan Deal. "We are honored to welcome this flagship company to Georgia and proud that our state's vast resources for the biomedical field will assist the company with the groundbreaking medical advances it is renowned for. Baxter's commitment to Georgia moves us closer to making Georgia the No. 1 state in which to do
"We would like to thank Governor Nathan Deal and the many other officials involved in the site selection process, and we look forward to becoming part of the Georgia community," said Ludwig Hantson, Ph.D., president of Baxter's BioScience business.
Baxter, unlike some other health-care companies, has seen consistent sales and profit growth in recent quarters as the medical devices, pharmaceuticals and biotechnologies it makes treat serious medical problems that can't be ignored, such as cancer, immune disorders and trauma according to a Wall Street Journal report.
For more news and information visit Blumberg Capital Partners.
No comments:
Post a Comment